K
Keros Therapeutics, Inc.
KROS · NASDAQ · Healthcare · 323M
Closing price
$11.95
+2.66% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
5.1×
Price / net assetsP/B
1.5×
Enterprise value / EBITDAEV/EBITDA
1.9×
Free cash flow yieldFCF yield
23.8%
Return on equityROE
28.7%
Operating margin
28.9%
Net debt / EBITDAbalance-sheet strength
-2.9×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.